Furthermore, the role of GLP-1R agonists in the treatment of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) is being actively explored (Siddeeque et al., 2024). Here, GLP1R is linked to early-onset autosomal dominant Alzheimer disease.